Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(CELZ)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
0.5300 USD   -3.64%
03/23Creative Medical Technology Seeks FDA Orphan Drug Designation for ImmCelz Platform
MT
03/23Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz« Platform for the Treatment of Brittle Type 1 Diabetes
PR
03/22Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz Platform Development
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

02/08/2023 | 08:00am EDT

Creative Medical Technology Holdings, Inc. announced that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. Food and Drug Administration (FDA) had previously cleared the Company's Investigational New Drug (IND) application within 30 days from submission. The Company believes that CELZ-201 leverages a unique approach to harnessing the power of Perinatal Tissue Derived Cells (PRDC) to multi-potentialities, including self-renewal ability, low antigenicity, reduced toxicity, and large-scale clinical expansion.

The primary objective of the study is to evaluate CELZ-201 as a treatment for patients with newly diagnosed Type 1 Diabetes. The company sponsored trial will be conducted at the University of Miami Health System in conjunction with the Diabetes Research Institute.


ę S&P Capital IQ 2023
All news about CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
03/23Creative Medical Technology Seeks FDA Orphan Drug Designation for ImmCelz Platform
MT
03/23Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA..
PR
03/22Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz Platfor..
AQ
03/21Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz« Platfo..
PR
03/21Creative Medical Technology Holdings, Inc. Announces Key Milestones Regarding Immcelz P..
CI
03/07Creative Medical Partners With Syneos Health Over Study of Potential Type 1 Diabetes Tr..
MT
03/07Creative Medical Technology Holdings Engages Highly Respected International CRO for Pha..
BU
02/14Three Year Follow-Up Results Confirm Efficacy of StemSpine« Procedure for Treating Chro..
BU
02/14Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data..
CI
02/08Top Midday Gainers
MT
More news
Analyst Recommendations on CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 0,43 M - -
Net income 2022 -4,97 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,18x
Yield 2022 -
Capitalization 7,46 M 7,46 M -
Capi. / Sales 2022 17,3x
Capi. / Sales 2023 9,04x
Nbr of Employees 4
Free-Float 97,5%
Chart CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Duration : Period :
Creative Medical Technology Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,53 $
Average target price 10,00 $
Spread / Average Target 1 787%
EPS Revisions
Managers and Directors
Timothy Warbington Chairman, President & Chief Executive Officer
Donald F. Dickerson Chief Financial Officer, Director & Senior VP
Courtney Bartlett Director-Clinical Development
Michael H. Finger Independent Director
Bruce S. Urdang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.39.07%7
REGENERON PHARMACEUTICALS, INC.13.65%87 515
VERTEX PHARMACEUTICALS8.87%80 827
WUXI APPTEC CO., LTD.-1.06%34 805
BIONTECH SE-14.66%31 155
GENMAB A/S-12.34%24 291
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer